Database→Bremelanotide (PT-141)

Tier 1Sexual HealthHormonalPREMIUM

Bremelanotide (PT-141)

Bremelanotide (PT-141 / Vyleesi) · Cyclic Melanocortin Analogue · MC4R-Mediated Sexual Desire Modulator

FDA approved June 21, 2019 (Vyleesi) for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin Technologies / AMAG Pharmaceuticals. First-in-class as-needed treatment for female HSDD. Not approved for male erectile dysfunction. WADA: not prohibited as of March 2026.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Bremelanotide (PT-141/Vyleesi) is an FDA-approved cyclic melanocortin analogue that acts centrally via MC4R on dopaminergic and noradrenergic sexual arousal pathways, the only approved HSDD treatment that works through the brain's sexual desire circuitry rather than vascular or monoamine mechanisms. Approved 2019 as the first as-needed treatment for female HSDD (versus daily flibanserin). Phase 2 data supports off-label use in male erectile dysfunction non-responsive to PDE5 inhibitors; combination bremelanotide plus PDE5i product in active Phase 2 development by Palatin.

🔒

Full Profile: Premium Members Only

The complete Bremelanotide (PT-141) profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use